+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cellular Immunotherapy Market by Type, Indication, Technology Type, End-Use - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011253
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cellular Immunotherapy Market grew from USD 11.23 billion in 2023 to USD 14.02 billion in 2024. It is expected to continue growing at a CAGR of 25.34%, reaching USD 54.60 billion by 2030.

Cellular immunotherapy, a transformative modality in healthcare, involves harnessing and modifying immune cells to fight diseases, primarily cancer. It includes treatments like CAR-T cell therapy, TCR therapy, and dendritic cell therapy. The necessity for cellular immunotherapy arises from the growing incidence of cancer and severe infections, coupled with the limitations of traditional treatments. Key applications span oncology, infectious diseases, autoimmune disorders, and regenerative medicine. End-users are primarily hospitals and cancer treatment centers, with increased focus on personalized medicine fostering its appeal. The market's growth is influenced by factors such as advancements in genetic engineering, supportive regulatory pathways, and substantial investment in R&D by both public and private entities. Opportunities abound with increasing clinical trials, potential expansion into non-oncological diseases, and collaboration between biotech firms and academic institutions. However, high treatment costs, complex production processes, stringent regulatory requirements, and potential side effects pose significant market challenges. For innovation, focusing on enhancing manufacturing efficiency, reducing costs, improving the specificity and safety of therapies, and exploring novel cell types such as NK cells and macrophages could prove beneficial. Moreover, developments in biomarker identification could lead to more targeted and effective therapies. The market is inherently dynamic and heavily research-driven, with a competitive landscape where new entrants can thrive through differentiation in technology and approach. Furthermore, partnerships and collaborations are crucial for accessing advanced technologies and scaling operations. As the market continuously evolves, aligning business strategies with cutting-edge research and regulatory trends will be pivotal for establishing a stronghold. Emphasizing patient-centric approaches and increasing awareness among healthcare professionals and patients could further enhance uptake and acceptance of cellular immunotherapy.

Understanding Market Dynamics in the Cellular Immunotherapy Market

The Cellular Immunotherapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Prevalence of cancer and advanced cell based therapies
    • Favorable government initiatives for cellular therapies R&D
    • Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
  • Market Restraints
    • High initial costs of devices and therapies
  • Market Opportunities
    • Technological advancements and new products for cellular immunotherapy
    • Increasing approvals of different cell-based immunotherapy drugs
  • Market Challenges
    • Product recalls and stringent regulatory approvals

Exploring Porter’s Five Forces for the Cellular Immunotherapy Market

Porter’s Five Forces framework further strengthens the insights of the Cellular Immunotherapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cellular Immunotherapy Market

External macro-environmental factors deeply influence the performance of the Cellular Immunotherapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cellular Immunotherapy Market

The Cellular Immunotherapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cellular Immunotherapy Market

The Cellular Immunotherapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cellular Immunotherapy Market

The Cellular Immunotherapy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cellular Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Apac Biotech Private Limited, AstraZeneca PLC, Atara Biotherapeutics, Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Celyad Oncology SA, Corning Incorporated, Dendreon Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glycostem Therapeutics B.V., Immatics N.V., Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., JW Therapeutics (Shanghai) Co., Ltd., Lonza Group Ltd., Merck KGaA, Novartis AG, Pfizer Inc., and Tessa Therapeutics Ltd..

Market Segmentation & Coverage

This research report categorizes the Cellular Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • CAR T-Cell Therapy
    • Dendritic Cell Therapy
    • NK Cell Therapy
    • Tumor-Infiltrating Lymphocytes Therapy
  • Indication
    • B-Cell Malignancies
    • Liver Cancer
    • Prostate Cancer
    • Renal Cell Carcinoma
  • Technology Type
    • Cytokines & Immunomodulators
    • Monoclonal Antibodies
  • End-Use
    • Cancer Institutes
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of cancer and advanced cell based therapies
5.1.1.2. Favorable government initiatives for cellular therapies R&D
5.1.1.3. Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
5.1.2. Restraints
5.1.2.1. High initial costs of devices and therapies
5.1.3. Opportunities
5.1.3.1. Technological advancements and new products for cellular immunotherapy
5.1.3.2. Increasing approvals of different cell-based immunotherapy drugs
5.1.4. Challenges
5.1.4.1. Product recalls and stringent regulatory approvals
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cellular Immunotherapy Market, by Type
6.1. Introduction
6.2. CAR T-Cell Therapy
6.3. Dendritic Cell Therapy
6.4. NK Cell Therapy
6.5. Tumor-Infiltrating Lymphocytes Therapy
7. Cellular Immunotherapy Market, by Indication
7.1. Introduction
7.2. B-Cell Malignancies
7.3. Liver Cancer
7.4. Prostate Cancer
7.5. Renal Cell Carcinoma
8. Cellular Immunotherapy Market, by Technology Type
8.1. Introduction
8.2. Cytokines & Immunomodulators
8.3. Monoclonal Antibodies
9. Cellular Immunotherapy Market, by End-Use
9.1. Introduction
9.2. Cancer Institutes
9.3. Hospitals
10. Americas Cellular Immunotherapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cellular Immunotherapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cellular Immunotherapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CELLULAR IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 2. CELLULAR IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CELLULAR IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CELLULAR IMMUNOTHERAPY MARKET DYNAMICS
TABLE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 36. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 39. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 58. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 61. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 62. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 65. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 73. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 97. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 110. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 114. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 118. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 131. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 134. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 146. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 147. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 148. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 150. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 151. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 152. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 154. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 182. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 191. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cellular Immunotherapy market, which are profiled in this report, include:
  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc.
  • Apac Biotech Private Limited
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Corning Incorporated
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glycostem Therapeutics B.V.
  • Immatics N.V.
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics (Shanghai) Co., Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Tessa Therapeutics Ltd.

Methodology

Loading
LOADING...

Table Information